Dr. Melear is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
11111 Research Blvd
Suite 400
Austin, TX 78759Phone+1 512-419-9733Fax+1 512-349-0406
Education & Training
- Baylor University Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2001
- Baylor University Medical CenterResidency, Internal Medicine, 1996 - 1999
- Texas Tech University Health Sciences Center School of MedicineClass of 1996
Certifications & Licensure
- TX State Medical License 1997 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Super Doctor SuperDoctors.com
Clinical Trials
- Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
- Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Start of enrollment: 2018 Feb 22
- Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias Start of enrollment: 2018 Oct 29
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsA phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.Sudhir Manda, Bertrand M Anz 3rd, Christopher Benton, E Randolph Broun, Habte A Yimer
Hematological Oncology. 2024-05-01 - Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.R C Coombes, Sacha Howell, Simon R Lord, Laura Kenny, Janine Mansi
Nature Communications. 2023-08-07 - 14 citationsDose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.R C Coombes, Sacha Howell, Simon R Lord, Laura Kenny, Janine Mansi
Nature Communications. 2023-07-24
Abstracts/Posters
- Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezom...Jason M. Melear, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b StudyJason M. Melear, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
- Blood Cancer Breakthroughs with Dr. Jason MelearFebruary 25th, 2020
- Blood Cancer Breakthroughs: Targeted Therapies Take the Lead in the Future of TreatmentFebruary 1st, 2020
- The Benefits and Risks to Consider in Clinical TrialsMay 18th, 2018
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: